Coronary/Structural Heart

HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001, an Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis

Share by Ken Dropiewski on

More in Coronary/Structural Heart:

Share this story

LAUSANNE, Switzerland & SAN DIEGO–(BUSINESS WIRE)– #Cardiology–HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Trial of HTX-001, an Investigational Cellular Reprogramming Therapy for Cardiac Fibrosis

See the full post here as oringinally posted on this site.

Ken has been in the cardiac, vascular, and interventional space for over 20 years. He is a Partner with McDermott + Bull Executive Search, recognized by Forbes as one of the industry's best with offices across North America and in Europe. Ken is hired by innovative cardiovascular device and biotech companies to help build their best teams possible at the executive level. Prior to search, Ken had an award winning commercial career at Boston Scientific and Johnson & Johnson to include such prestigious awards as President's Club, Ring Club, and Grand Awards. dropiewski@mbexec.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*